Email Alert RSS
Volume 12 Issue 1
Jan.  2021
Turn off MathJax
Article Contents
Abstract
References
FAN Jun-ping, XIAO Meng, WANG Jing-lan, CHEN Yu, ZHANG Dong, XIA Peng, KE Fan-hang, ZHAO Jing, YANG Yan-li, SUN Xue-feng, ZHAO Ying, XU Ying-chun. Value of Biofire Filmarray Pneumonia Panel in Evaluating Secondary Infection in Critically Ill Patients with Coronavirus Disease 2019[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 38-43. DOI: 10.12290/xhyxzz.20200264
Citation: FAN Jun-ping, XIAO Meng, WANG Jing-lan, CHEN Yu, ZHANG Dong, XIA Peng, KE Fan-hang, ZHAO Jing, YANG Yan-li, SUN Xue-feng, ZHAO Ying, XU Ying-chun. Value of Biofire Filmarray Pneumonia Panel in Evaluating Secondary Infection in Critically Ill Patients with Coronavirus Disease 2019[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 38-43. DOI: 10.12290/xhyxzz.20200264
shu

Value of Biofire Filmarray Pneumonia Panel in Evaluating Secondary Infection in Critically Ill Patients with Coronavirus Disease 2019

  • 1.

    Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 2.

    Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 3.

    Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 4.

    School of Clinical Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds: 

National Major Science and Technology Project for the Control and Prevention of Major Infectious Diseases of China 2017ZX10103004

CAMS Innovation Fund for Medical Sciences (CIFMS) 2018-I2M-1-003

Beijing Nova Program Z201100006820127

More Information
  • Received Date: October 15, 2020
  • Accepted Date: December 09, 2020
  • Issue Publish Date: January 29, 2021
    Graphical Abstract
    • Abstract
  •   Objective  To explore the application value of Biofire Filmarry pneumonia panel (PN) in detection of secondary and concomitant pathogen among critically ill patients with coronavirus disease 2019(COVID-19).
      Methods  We consecutively included and analyzed the clinical data of critically ill patients with COVID-19 transferred to the ICU from February to April 2020 in the Sino-French Campus of Wuhan Tongji Hospital. Samples of Bronchoalveolar lavage fluid obtained by bedside bronchoscopy were sent for Biofire Filmarray PN and standard culture concomitantly. We compared the results of two methods and evaluated their concordance.
      Results  In total, 21 critically ill patients with COVID-19 were included and 54 samples were tested, including 33 (61.1%) Biofire Filmarray PN tests (21 patients) and 21 (38.9%) standard cultures (14 patients), in which 19 pairs (38 samples) underwent both tests simultaneously. In Biofire Filmarray PN group, the turnaround time was about 1 hour. There were 74 positive results in 32 samples (97.0%) from 20 patients, including 29 cases(39.2%) of Acinetobacter baumannii complex, 21 cases (28.4%) of Pseudomonas aeruginosa, 16 cases (21.6%)of Klebsiella pneumoniae, 5 cases (6.8%) of Escherichia coli, 1 case (1.4%)each of Enterobacter cloacae, Haemophilus influenzae, and respiratory syncytial virus. In the standard culture group, the turnaround time was about 3 days. 19 positive results returned in 16 (76.2%) samples from 11 patients, including 8 cases (42.1%) of Pseudomonas aeruginosa, 6 cases (31.6%) of Acinetobacter baumannii, 4 cases (21.1%) of Stenotrophomonas malt and 1 case (5.3%) of Myxobacterium. Among the 19 pairs of "back-to-back" specimens, 15 pairs were concordant, and the agreement ratio was 78.9%.
      Conclusions  Acinetobacter baumannii and Pseudomonas aeruginosa may be the common pathogens of secondary or concomitant infection in critically ill patients with COVID-19. Biofire Filmarray PN is a rapid diagnostic test and has application value in such patients; its sensitivity and accuracy require further investigation with larger sample sizes.
    • FullText(HTML)
    • References (12)
  • [1]
    Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysio-logy, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review [J]. JAMA, 2020, 324:782-793. DOI: 10.1001/jama.2020.12839
    [2]
    Kim D, Quinn J, Pinsky B, et al. Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens [J]. JAMA, 2020, 323:2085-2086. DOI: 10.1001/jama.2020.6266
    [3]
    Lansbury L, Lim B, Baskaran V, et al. Co-infections in people with COVID-19: a systematic review and meta-analysis [J]. J Infect, 2020, 81:266-275. DOI: 10.1016/j.jinf.2020.05.046
    [4]
    Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America [J]. Am J Respir Crit Care Med, 2019, 200:e45-e67. DOI: 10.1164/rccm.201908-1581ST
    [5]
    Edin A, Eilers H, Allard A. Evaluation of the Biofire Filmarray Pneumonia panel plus for lower respiratory tract infections [J]. Infect Dis (Lond), 2020, 52:479-488. DOI: 10.1080/23744235.2020.1755053
    [6]
    Buchan BW, Windham S, Balada-Llasat JM, et al. Practical Comparison of the BioFire FilmArray Pneumonia Panel to Routine Diagnostic Methods and Potential Impact on Antimicrobial Stewardship in Adult Hospitalized Patients with Lower Respiratory Tract Infections [J]. J Clin Microbiol, 2020, 58:e00135-20. DOI: 10.1128/JCM.00135-20
    [7]
    McCullers JA. The co-pathogenesis of influenza viruses with bacteria in the lung [J]. Nat Rev Microbiol, 2014, 12:252-262. DOI: 10.1038/nrmicro3231
    [8]
    Paules C, Subbarao K. Influenza [J]. Lancet, 2017, 390:697-708. DOI: 10.1016/S0140-6736(17)30129-0
    [9]
    Clancy CJ, Nguyen MH. COVID-19, superinfections and antimicrobial development: What can we expect? [J]. Clin Infect Dis, 2020:ciaa524. doi: 10.1093/cid/ciaa524.
    [10]
    Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study [J]. Lancet Respir Med, 2020, 8:475-481. DOI: 10.1016/S2213-2600(20)30079-5
    [11]
    Gadsby NJ, Russell CD, McHugh MP, et al. Comprehen-sive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia [J]. Clin Infect Dis, 2016, 62:817-823. DOI: 10.1093/cid/civ1214
    [12]
    Lee SH, Ruan SY, Pan SC, et al. Performance of a multiplex PCR pneumonia panel for the identification of respiratory pathogens and the main determinants of resistance from the lower respiratory tract specimens of adult patients in intensive care units [J]. J Microbiol Immunol Infect, 2019, 52:920-928. DOI: 10.1016/j.jmii.2019.10.009
    • Related Articles

  • Cited by

    Periodical cited type(1)

    1. 周承勃森，贾红，鞠长燕. 呼吸道病原体检测平台应用进展. 国际检验医学杂志. 2022(24): 3057-3064 .

    Other cited types(1)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1492) PDF downloads (116) Cited by(2)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close